MX2015002842A - Prevencion de la recurrencia pulmonar del cancer con cisplatino lipido-complejado. - Google Patents

Prevencion de la recurrencia pulmonar del cancer con cisplatino lipido-complejado.

Info

Publication number
MX2015002842A
MX2015002842A MX2015002842A MX2015002842A MX2015002842A MX 2015002842 A MX2015002842 A MX 2015002842A MX 2015002842 A MX2015002842 A MX 2015002842A MX 2015002842 A MX2015002842 A MX 2015002842A MX 2015002842 A MX2015002842 A MX 2015002842A
Authority
MX
Mexico
Prior art keywords
inhalation
administration
bone
lung
osteosarcoma
Prior art date
Application number
MX2015002842A
Other languages
English (en)
Spanish (es)
Inventor
Matthew M Parris
Forrest H Anthony
Edwin J Thomas
Quangtao Zhang
Original Assignee
Eleison Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eleison Pharmaceuticals LLC filed Critical Eleison Pharmaceuticals LLC
Publication of MX2015002842A publication Critical patent/MX2015002842A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2015002842A 2012-09-04 2013-09-04 Prevencion de la recurrencia pulmonar del cancer con cisplatino lipido-complejado. MX2015002842A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261743398P 2012-09-04 2012-09-04
PCT/US2013/058025 WO2014039533A2 (en) 2012-09-04 2013-09-04 Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin

Publications (1)

Publication Number Publication Date
MX2015002842A true MX2015002842A (es) 2015-08-12

Family

ID=50187920

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002842A MX2015002842A (es) 2012-09-04 2013-09-04 Prevencion de la recurrencia pulmonar del cancer con cisplatino lipido-complejado.

Country Status (10)

Country Link
US (1) US11291644B2 (https=)
EP (1) EP2892524B1 (https=)
JP (1) JP2015530387A (https=)
CN (4) CN112451486A (https=)
CA (1) CA2883703C (https=)
DK (1) DK2892524T3 (https=)
ES (1) ES2848025T3 (https=)
MX (1) MX2015002842A (https=)
PL (1) PL2892524T3 (https=)
WO (1) WO2014039533A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
DK2892524T3 (da) 2012-09-04 2021-01-25 Eleison Pharmaceuticals LLC Forebyggelse af pulmonalt kræfttilbagefald med lipid-komplekseret cisplatin
US11478504B2 (en) 2013-07-08 2022-10-25 International Dehydrated Foods, Inc. Compositions and methods for preventing/treating metabolic syndrome
MX375862B (es) * 2013-07-08 2025-03-07 Int Dehydrated Foods Inc Composiciones preparadas de aves de corral y metodos de su uso.
AU2015227247A1 (en) * 2014-03-07 2016-09-15 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with Notch 1 antibodies
CN109568336B (zh) * 2018-12-29 2021-10-08 江苏靶标生物医药研究所有限公司 一种铂类化合物和硫酸软骨素的组合物及其应用
CA3210619A1 (en) 2021-03-11 2022-09-15 Dipanjan Pan Compositions and methods for removing bio-synthetic nano-particles from bodily fluids
WO2025264889A1 (en) * 2024-06-19 2025-12-26 Pharmosa Biopharm Inc. Nebulizer kits and uses thereof

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (https=) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4451447A (en) 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5435989A (en) 1982-03-30 1995-07-25 Vestar, Inc. Method of targeting a specific location in a body
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
US4981692A (en) 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4590001A (en) 1983-03-28 1986-05-20 Stjernholm Rune L Platinum bound to transferrin for use in the treatment of breast tumors
USRE33071E (en) 1983-03-28 1989-09-26 Platinum bound to transferrin for use in the treatment of breast tumors
US4572425A (en) 1983-08-01 1986-02-25 Russell William S Reusable container
EP0153955A1 (en) 1983-09-06 1985-09-11 Health Research, Inc. Liposome delivery method for decreasing the toxicity of an antitumor drug
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
CA1270198C (en) 1984-08-08 1990-06-12 Marcel B Bally ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH0665648B2 (ja) 1985-09-25 1994-08-24 塩野義製薬株式会社 白金系抗癌物質の安定な凍結真空乾燥製剤
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US5041581A (en) 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5117022A (en) 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5320906A (en) 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
ATE113468T1 (de) 1987-07-29 1994-11-15 Liposome Co Inc Verfahren zur trennung von teilchen nach grösse.
IL83380A (en) 1987-07-30 1991-04-15 Teva Pharma Stable aqueous cisplatin solutions
DE68901733T2 (de) 1988-03-04 1993-03-25 Takeda Chemical Industries Ltd Liposom-zusammensetzung.
US5141751A (en) 1988-06-29 1992-08-25 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structures
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551169A1 (en) 1992-01-10 1993-07-14 Takeda Chemical Industries, Ltd. Liposome composition and production thereof
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5958449A (en) 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
CN1088777A (zh) 1992-12-18 1994-07-06 丛繁滋 用于癌病灶直接给药的化疗药物制剂的制备方法
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5780054A (en) 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
EP0896816A4 (en) 1996-02-26 2002-06-12 Daiichi Seiyaku Co LIPOSOME AND LIPOSOME DISPERSION
PT910382E (pt) 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
ATE252372T1 (de) 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
AU7711096A (en) 1996-12-03 1998-06-29 Rijsuniversiteit Utrecht Cisplatinum comprising pharmaceutical
AU741439B2 (en) 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
CN1191067C (zh) 1997-02-05 2005-03-02 法玛西雅厄普约翰美国公司 高不溶性铂配合物的脂质复合物和脂质体
FR2759293B1 (fr) 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
US6630168B1 (en) 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US7348025B2 (en) 1997-09-23 2008-03-25 Research Development Foundation Small particle liposome aerosols for delivery of anticancer drugs
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
CA2248592A1 (en) 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
ES2156506B1 (es) 1998-10-14 2002-03-01 Sumitomo Chemical Co Metodo para la produccion de oxido de propileno.
KR20010111564A (ko) 1998-11-12 2001-12-19 프랭크 쥐. 필키윅즈 흡입 시스템
US20050074499A1 (en) 1999-03-17 2005-04-07 Mitsubishi Chemical Corporation Ligand-bonded complex
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
WO2000074634A2 (en) 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
WO2001032139A2 (en) 1999-11-05 2001-05-10 Seed Capital Investment-2 (Sci-2) B.V. Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
EP1242106A4 (en) 1999-12-04 2008-08-27 Res Dev Foundation IMPROVING INHALATION THERAPY USING CARBON GAS
DE60123583T2 (de) 2000-02-04 2007-08-09 Lipoxen Technologies Ltd. Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
US20020012998A1 (en) 2000-03-29 2002-01-31 Igor Gonda Cationic liposomes
WO2001082892A2 (de) 2000-05-02 2001-11-08 Pharmacept Gmbh Wirkstoffhaltige liposome
US6998393B2 (en) 2000-06-23 2006-02-14 Biopharm Solutions, Inc. Aquespheres, their preparation and uses thereof
JP2004501955A (ja) 2000-06-30 2004-01-22 アイネックス　ファーマシューティカルズ　コーポレイション リポソーム抗新生物薬剤およびその使用
WO2002060412A2 (en) 2001-02-01 2002-08-08 Board Of Regents Stabilised polymeric aerosols for pulmonary gene delivery
JP2004529929A (ja) 2001-04-23 2004-09-30 ニュクリスト ファーマシューティカルズ コーポレーション アポトーシスの誘導およびマトリックスメタロプロテイナーゼの阻害のための金属の使用
US20030143162A1 (en) 2001-05-18 2003-07-31 Speirs Robert John Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
AU2002323151A1 (en) 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US6793912B2 (en) 2001-08-20 2004-09-21 Transave Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
CA2456746A1 (en) 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
JP2005530704A (ja) 2002-03-05 2005-10-13 トランセイブ， インク． 細胞内感染を予防及び治療するための吸入システム
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040022842A1 (en) 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
EP1545459A4 (en) 2002-08-02 2007-08-22 Transave Inc PLATINUM AGGREGATES, AND METHOD FOR MANUFACTURING THE SAME
US9186322B2 (en) 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
PT1581236E (pt) 2002-10-29 2013-12-24 Insmed Inc Libertação prolongada de anti-infecciosos
AU2003298738A1 (en) 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
AU2005206163B2 (en) 2004-01-14 2011-06-30 Gilead Sciences, Inc. Lipid-based dispersions useful for drug delivery
US20070065522A1 (en) 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
CA2559722A1 (en) 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
US8221739B2 (en) * 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
WO2005112957A1 (en) 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
MX2007004955A (es) 2004-11-08 2007-06-14 Transave Inc Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
JP2008523151A (ja) 2004-12-14 2008-07-03 トランセイブ， インク． 生理活性物質を含む脂質粒子、その調製法及び使用法
WO2006113181A2 (en) * 2005-04-08 2006-10-26 University Of Florida Research Foundation, Inc. Stem-like cells in bone sarcomas
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20090130194A1 (en) * 2005-11-08 2009-05-21 Transave, Inc. Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously
US20070190182A1 (en) 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007064658A2 (en) 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
GR20060100144A (el) 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
AU2010248833B2 (en) * 2009-05-14 2015-08-20 Oatmeal Biotechnologies Group, L.L.C. Platform technologies for spontaneously occurring diseases
EP2538956A4 (en) 2010-02-22 2015-04-22 Edge Therapeutics Inc METHODS AND COMPOSITIONS FOR TREATING HEMORRHAGIC BRAIN DISORDERS
AU2011278931A1 (en) * 2010-07-16 2013-03-07 Epeius Biotechnologies Corporation Targeted nanoparticles for cancer and other disorders
DK2892524T3 (da) 2012-09-04 2021-01-25 Eleison Pharmaceuticals LLC Forebyggelse af pulmonalt kræfttilbagefald med lipid-komplekseret cisplatin

Also Published As

Publication number Publication date
US20140065205A1 (en) 2014-03-06
EP2892524A4 (en) 2016-07-06
ES2848025T3 (es) 2021-08-05
WO2014039533A3 (en) 2015-07-16
JP2015530387A (ja) 2015-10-15
PL2892524T3 (pl) 2021-10-25
WO2014039533A2 (en) 2014-03-13
CA2883703C (en) 2021-10-19
HK1212593A1 (en) 2016-06-17
CN112451486A (zh) 2021-03-09
CN121606602A (zh) 2026-03-06
EP2892524B1 (en) 2020-11-25
EP2892524A2 (en) 2015-07-15
US11291644B2 (en) 2022-04-05
CN115414384A (zh) 2022-12-02
CA2883703A1 (en) 2014-03-13
CN105025904A (zh) 2015-11-04
DK2892524T3 (da) 2021-01-25

Similar Documents

Publication Publication Date Title
US11291644B2 (en) Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
ES2409755T3 (es) Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado
TWI626061B (zh) 治療癌症之奈米粒子及其用途
Li et al. Advances in bone‐targeted drug delivery systems for neoadjuvant chemotherapy for osteosarcoma
KR20110132446A (ko) 키나아제 단백질 결합 억제제
US20100151006A1 (en) Cancer therapy sensitizer
JP2010180210A (ja) 併用薬剤を送達するための組成物
AU2009257536A1 (en) Treatment of cancers of the blood using selected glycomimetic compounds
Wu et al. Efferocytosis nanoinhibitors to promote secondary necrosis and potentiate the immunogenicity of conventional cancer therapies for improved therapeutic benefits
JP2016528217A (ja) 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
Liang et al. Pictilisib enhances the antitumor effect of doxorubicin and prevents tumor-mediated bone destruction by blockade of PI3K/AKT pathway
Xu et al. Targeted inhibition of STAT3 (Tyr705) by xanthatin alleviates osteoarthritis progression through the NF-κB signaling pathway
Ledwitch et al. Taxol: efficacy against oral squamous cell carcinoma
Lan et al. Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers
JP4671962B2 (ja) デフィブロチド単独又は他の抗腫瘍剤との組み合わせを含む抗腫瘍製剤
Sellers et al. From conventional to cutting edge: an exploration of osteosarcoma treatments
BRPI0715521A2 (pt) mÉtodos, composiÇÕes e artigos de fabricaÇço para contribuir para o tratamento de cÂnceres
He et al. Liposomal all-trans retinoic acid boosts anti-tumor immunity of radiotherapy via mitigating cancer stemness and remedying tumor microenvironment
WO2023062516A1 (en) 2-deoxy-d-glucose for use in disease therapy
Weber et al. Renal cell carcinoma bone metastasis: epidermal growth factor receptor targeting.
HK1212593B (en) Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
EP3920906B1 (en) Bisphosphonate-linked compounds
JP2016222711A (ja) トリシリビン含有組成物、及びその使用方法
WO2021239730A1 (en) Nanoparticles, ionizing radiation and innovative therapeutic combinations thereof